경피 독성 시험 시장 예측(-2030년) : 유형별, 시험법별, 시험 유형별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Dermal Toxicity Testing Market is accounted for $2.32 billion in 2023 and is expected to reach $4.60 billion by 2030 growing at a CAGR of 10.3% during the forecast period. Dermal toxicity testing is a scientific method employed to assess the potential harmful effects of chemical substances when they come into contact with the skin. This type of testing is crucial for evaluating the safety of various products, including cosmetics, pharmaceuticals, and industrial chemicals. Various parameters are assessed during dermal toxicity testing, such as skin appearance, erythema (redness), edema (swelling), and other signs of irritation.

According to the Cancer Research Institute, the number of active drugs in development grew by more than 90%, to 3,876 in 2019. Long-term rodent carcinogenicity studies for assessing the carcinogenic potential of drugs in humans are currently being examined.

Market Dynamics:

Driver:

Increasing research and development activities

The growth in R&D activities underscores the pivotal role of the development of new products and formulations to introduce innovative and safe products to the market. Comprehensive dermal toxicity testing becomes imperative to assess the safety profile of these advancements. Further, by the need to align with evolving regulatory standards, safeguard public health, and instill consumer confidence in the safety of newly developed products, the demand for dermal toxicity testing services is propelled.

Restraint:

High cost

Dermal toxicity testing requires specialized facilities and equipment to ensure accurate and reliable results. The costs of maintaining such facilities, acquiring and maintaining testing equipment, and employing skilled personnel can be significant. The complexity and diversity of substances that require testing further contribute to the costs. Furthermore, as regulatory requirements evolve, additional tests or updated methodologies may be necessary, leading to increased costs for compliance, which is hampering this market expansion.

Opportunity:

Rising consumer awareness

Rising awareness regarding skin health and safety prompts consumers to scrutinize product labels and demand transparency from manufacturers. Consumers are becoming more conscious of the potential risks associated with exposure to certain chemicals present in personal care products, cosmetics, and pharmaceuticals. Additionally, this emphasis on safety aligns with the broader trend of consumers seeking products that prioritize health and environmental sustainability, which are driving this market size.

Threat:

Limited standardization

The absence of standardized protocols and guidelines made it challenging to make accurate risk assessments and interpret test results obtained from different laboratories or studies. It also made it difficult to establish consistent criteria for determining the safety of substances in relation to dermal exposure. Moreover, the lack of harmonization resulted in inefficiencies and increased costs for both regulators and industry stakeholders, which are hindering this market expansion.

Covid-19 Impact

The COVID-19 pandemic has had several negative impacts on the dermal toxicity testing market. The dermal toxicity testing market relies heavily on the pharmaceutical, cosmetic, and chemical sectors, all of which experienced disruptions during the pandemic. Laboratory closures, restricted access to facilities, and limitations on workforce mobility impeded the smooth conduct of dermal toxicity tests, affecting timelines for product approvals and introductions. Furthermore, the economic downturn has prompted some businesses to reconsider their investments in non-essential testing services, affecting overall market growth.

The in-silico modeling segment is expected to be the largest during the forecast period

The in-silico modeling segment is estimated to hold the largest share, due to they aim to provide accurate predictions of dermal toxicity by simulating molecular interactions, absorption rates, and potential adverse effects on the skin. These models contribute to the reduction of animal testing, aligning with ethical considerations and regulatory efforts to minimize animal use in testing procedures. In addition, advancements in technology, such as machine learning and artificial intelligence, enhance the accuracy and reliability of in-silico models, making them valuable tools in toxicology assessments which are driving this segment's growth.

The skin corrosion tests segment is expected to have the highest CAGR during the forecast period

The skin corrosion tests segment is anticipated to have highest CAGR during the forecast period. It refers to severe damage to the skin, often characterized by the destruction of skin tissue, leading to chemical burns. These tests typically involve the application of the test substance to the skin of experimental animals or in vitro models, and observations are made to determine the extent of skin damage. Furthermore, the results help classify substances as corrosive or non-corrosive, guiding regulatory decisions and safety assessments by providing essential data for product safety assessments, which is boosting this segment expansion.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to a dynamic landscape influenced by factors such as industrial growth, regulatory developments, and increasing awareness of product safety. The region encompasses diverse economies, including China, Japan, India, South Korea, and others, contributing to ensuring the safety of products through robust toxicity testing protocols. Moreover, increased awareness among consumers regarding personal care and pharmaceutical products further propels the demand for comprehensive dermal toxicity testing in this region.

Region with highest CAGR:

Europe is expected to witness highest CAGR over the projection period, owing to a strong focus on consumer safety and cutting-edge testing methodologies, with a notable shift towards alternative methods such as in vitro and in silico models. Key players such as Charles River Laboratories International, MatTek Corporation, Intertek Group, and GE Healthcare contribute to the accuracy and efficiency of dermal toxicity assessments. Further, stringent regulatory standards set by agencies like the U.S. Environmental Protection Agency (EPA) and the Food and Drug Administration (FDA) emphasize the importance of comprehensive toxicity testing, thereby driving this region.

Key players in the market

Some of the key players in the Dermal Toxicity Testing Market include SGS S.A, Bio-Rad Laboratories Inc., Charles River Laboratories International, Inc., Catalent, Inc., Eurofins Scientific Inc, Thermo Fisher Scientific, Inc., Covance, Inc , GE Healthcare, Qiagen N.V., Merck KgaA, Intertek Group, MatTek Corporation and Evotec.

Key Developments:

In December 2023, GE HealthCare and Nantworks AirStrip announced an agreement to Commercialize Integrated Patient Monitoring and Cardiac Data Visualization for Healthcare Systems.

In December 2023, SGS is pleased to announce the signing of an agreement to divest its crop science operations in 14 countries to Eurofins Scientific.

In November 2023, GE HealthCare (Nasdaq: GEHC) and Masimo announced a joint agreement to integrate Masimo Signal Extraction Technology (SET) pulse oximetry into GE HealthCare's Portrait Mobile wireless and wearable patient monitoring solution.

In October 2023, SGS is pleased to have signed an agreement to divest its US powertrain testing operations as part of its strategic portfolio evolution to Columbia River Partners, a private equity firm focused on the industrials, business services and IT services sectors.

Types Covered:

• Product
• Services
• Other Types

Testing Methods Covered:

• In-vitro Testing
• In-silico Modeling
• In-vivo Testing

Test Types Covered:

• Phototoxicity Tests
• Skin Irritation Tests
• Skin Sensitization Tests
• Skin Corrosion Tests
• Other Test Types

End Users Covered:

• Cosmetics and Personal Care Products Industry
• Chemical Industry
• Healthcare Industry
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Dermal Toxicity Testing Market, By Type

• 5.1 Introduction
• 5.2 Product
• 5.3 Services
  • 5.3.1 Inhouse Services
  • 5.3.2 Outsource Services
• 5.4 Other Types

6 Global Dermal Toxicity Testing Market, By Testing Method

• 6.1 Introduction
• 6.2 In-vitro Testing
• 6.3 In-silico Modeling
• 6.4 In-vivo testing

7 Global Dermal Toxicity Testing Market, By Test Type

• 7.1 Introduction
• 7.2 Phototoxicity Tests
• 7.3 Skin Irritation Tests
• 7.4 Skin Sensitization Tests
• 7.5 Skin Corrosion Tests
• 7.6 Other Test Types

8 Global Dermal Toxicity Testing Market, By End User

• 8.1 Introduction
• 8.2 Cosmetics and Personal Care Products Industry
• 8.3 Chemical Industry
• 8.4 Healthcare Industry
• 8.5 Other End Users

9 Global Dermal Toxicity Testing Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 SGS S.A
• 11.2 Bio-Rad Laboratories Inc.
• 11.3 Charles River Laboratories International, Inc.
• 11.4 Catalent, Inc.
• 11.5 Eurofins Scientific Inc
• 11.6 Thermo Fisher Scientific, Inc.
• 11.7 Covance, Inc
• 11.8 GE Healthcare
• 11.9 Qiagen N.V.
• 11.10 Merck KgaA
• 11.11 Intertek Group
• 11.12 MatTek Corporation
• 11.13 Evotec